<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02781584</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-384-3914</org_study_id>
    <nct_id>NCT02781584</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of selonsertib
      (SEL; formerly GS-4997), GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis
      (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 13, 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Cohorts 1-6 and 9 will be enrolled sequentially while Cohorts 7 and 8 will be randomized in parallel.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Laboratory Abnormalities</measure>
    <time_frame>Up to 12 weeks plus 30 days</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>SEL (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-0976 (2 x 10 mg capsules) for 12 weeks
Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9674 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9674 (3 x 10 mg tablets) for 12 weeks
Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL+GS-9674 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL+GS-0976 (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + GS-0976 (1 x 20 mg tablet) for 12 weeks
Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-0976+GS-9674 (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-0976 (1 x 20 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-0976 Cirrhotic (Cohort 7)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-0976 (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9674 Cirrhotic (Cohort 8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9674 (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEL + GS-0976 + GS-9674 (Cohort 9)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL (1 x 18 mg tablet) + GS-0976 (1 x 20 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>SEL (Cohort 1)</arm_group_label>
    <arm_group_label>SEL+GS-9674 (Cohort 4)</arm_group_label>
    <arm_group_label>SEL+GS-0976 (Cohort 5)</arm_group_label>
    <arm_group_label>SEL + GS-0976 + GS-9674 (Cohort 9)</arm_group_label>
    <other_name>GS-4997</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-0976</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>GS-0976 (Cohort 2)</arm_group_label>
    <arm_group_label>SEL+GS-0976 (Cohort 5)</arm_group_label>
    <arm_group_label>GS-0976+GS-9674 (Cohort 6)</arm_group_label>
    <arm_group_label>GS-0976 Cirrhotic (Cohort 7)</arm_group_label>
    <arm_group_label>SEL + GS-0976 + GS-9674 (Cohort 9)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9674</intervention_name>
    <description>Administered orally once daily</description>
    <arm_group_label>GS-9674 (Cohort 3)</arm_group_label>
    <arm_group_label>SEL+GS-9674 (Cohort 4)</arm_group_label>
    <arm_group_label>GS-0976+GS-9674 (Cohort 6)</arm_group_label>
    <arm_group_label>GS-9674 Cirrhotic (Cohort 8)</arm_group_label>
    <arm_group_label>SEL + GS-0976 + GS-9674 (Cohort 9)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Males and females between 18-75 years of age; inclusive based on the date of the
             screening visit

          -  Willing and able to provide informed consent prior to any study specific procedures
             being performed

          -  Meets the following conditions (Cohorts 1-6 and 9):

               -  Clinical diagnosis of non-alcoholic fatty liver disease, screening FibroTest® &lt;
                  0.75, unless a historical liver biopsy within 12 months of screening does not
                  reveal cirrhosis, screening magnetic resonance imaging - proton density fat
                  fraction (MRI-PDFF) with ≥ 10% steatosis, and screening magnetic resonance
                  elastography (MRE) with liver stiffness ≥ 2.88 kPa OR

               -  A historical liver biopsy within 12 months of screening consistent with NASH
                  (defined as the presence of steatosis, inflammation, and ballooning) with stage
                  2-3 fibrosis according to the NASH Clinical Research Network (CRN) classification
                  (or equivalent) and no documented weight loss &gt; 5% between the date of the liver
                  biopsy and screening

          -  For Cohorts 7 and 8, subjects must have a clinical diagnosis of NAFLD and have at
             least one of the following criteria (a-d): a) Screening MRE with liver stiffness ≥
             4.67 kPa; b) A historical FibroScan ≥ 14 kPa within 6 months of Screening; C)
             Screening FibroTest® ≥ 0.75; d) A historical liver biopsy consistent with stage 4
             fibrosis according to the NASH CRN classification (or equivalent)

        Key Exclusion Criteria:

          -  Pregnant or lactating females

          -  Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

          -  Any history of decompensated liver disease, including ascites, hepatic encephalopathy
             or variceal bleeding

          -  For Cohorts 7 and 8, Child-Pugh-Turcotte (CPT) score &gt; 6

          -  History of liver transplantation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

